In an open-label RCT of 60 kidney transplant recipients (of 100 planned) with late active AMR and de novo DSA, adding bortezomib to standard care did not improve the 12-month composite endpoint (40.0% vs 33.3%; p=0.59) and raised serious adverse events (76.7% vs 46.7%).
RCTn = 60
Snanoudj et al. Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial